CN1391919A - Lifuji oral liquor - Google Patents
Lifuji oral liquor Download PDFInfo
- Publication number
- CN1391919A CN1391919A CN 01114111 CN01114111A CN1391919A CN 1391919 A CN1391919 A CN 1391919A CN 01114111 CN01114111 CN 01114111 CN 01114111 A CN01114111 A CN 01114111A CN 1391919 A CN1391919 A CN 1391919A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- volatile oil
- group
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims abstract description 30
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 20
- 239000000341 volatile oil Substances 0.000 claims abstract description 12
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims abstract description 10
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims abstract description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 10
- 241000489492 Arisaema Species 0.000 claims abstract description 7
- 210000000941 bile Anatomy 0.000 claims abstract description 7
- 239000000706 filtrate Substances 0.000 claims abstract description 7
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims abstract description 4
- 229920000053 polysorbate 80 Polymers 0.000 claims abstract description 4
- 235000014375 Curcuma Nutrition 0.000 claims abstract 2
- 244000111489 Gardenia augusta Species 0.000 claims abstract 2
- 239000007788 liquid Substances 0.000 claims description 13
- 241000208340 Araliaceae Species 0.000 claims description 6
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 6
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 6
- 235000008434 ginseng Nutrition 0.000 claims description 6
- 239000009636 Huang Qi Substances 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 4
- 239000006185 dispersion Substances 0.000 claims description 3
- 239000000284 extract Substances 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 3
- 239000000796 flavoring agent Substances 0.000 claims description 3
- 235000019634 flavors Nutrition 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 239000003921 oil Substances 0.000 claims description 3
- 238000012856 packing Methods 0.000 claims description 3
- 239000002244 precipitate Substances 0.000 claims description 3
- 238000004064 recycling Methods 0.000 claims description 3
- 235000020374 simple syrup Nutrition 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 claims description 3
- 238000004659 sterilization and disinfection Methods 0.000 claims description 3
- 244000164439 Curcuma angustifolia Species 0.000 claims 1
- 241000208966 Polygala Species 0.000 claims 1
- 241000545442 Radix Species 0.000 claims 1
- 239000013583 drug formulation Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 8
- 241001127714 Amomum Species 0.000 abstract 1
- 241000202726 Bupleurum Species 0.000 abstract 1
- 244000163122 Curcuma domestica Species 0.000 abstract 1
- 235000002848 Cyperus flabelliformis Nutrition 0.000 abstract 1
- 240000001505 Cyperus odoratus Species 0.000 abstract 1
- 235000018958 Gardenia augusta Nutrition 0.000 abstract 1
- 241000146384 Glaux Species 0.000 abstract 1
- 240000007164 Salvia officinalis Species 0.000 abstract 1
- 229940107666 astragalus root Drugs 0.000 abstract 1
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 235000005412 red sage Nutrition 0.000 abstract 1
- 239000006188 syrup Substances 0.000 abstract 1
- 235000020357 syrup Nutrition 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 description 12
- 241000700159 Rattus Species 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 238000012360 testing method Methods 0.000 description 6
- 206010016256 fatigue Diseases 0.000 description 5
- 238000000465 moulding Methods 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 4
- 230000036407 pain Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- FLDSMVTWEZKONL-AWEZNQCLSA-N 5,5-dimethyl-N-[(3S)-5-methyl-4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-1,4,7,8-tetrahydrooxepino[4,5-c]pyrazole-3-carboxamide Chemical compound CC1(CC2=C(NN=C2C(=O)N[C@@H]2C(N(C3=C(OC2)C=CC=C3)C)=O)CCO1)C FLDSMVTWEZKONL-AWEZNQCLSA-N 0.000 description 2
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 2
- 229960002646 scopolamine Drugs 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 235000019615 sensations Nutrition 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000009182 swimming Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 1
- 206010013789 Dry throat Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 101710102916 Ichor Proteins 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 206010043269 Tension headache Diseases 0.000 description 1
- 208000008548 Tension-Type Headache Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 206010020765 hypersomnia Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000003771 laboratory diagnosis Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The Lifuji oral liquor is a medicine for treating chronic fatigue syndrome with high curative effect. The technological scheme includes extracting volatile oil from curcuma root, bupleurum root, amomum fruit, nutagrass flatsedge rhizome and Chuanxiong rhizome; decocting red sage, astragalus root, milkwort root, cape jasmine, arisaema with bile and the medicine residue after extracting volatile oil; merging the volatile oil and the decoction; concentration; fitlering after ethanol dissolving, recovering filtrate, centrifuging, adding Tween-80, and mixing with syrup and water.
Description
The present invention relates to a kind of oral liquid for the treatment of chronic fatigue syndrome.
In developed country, the prevalence of suffering from chronic fatigue syndrome is about 3/1000ths.According to statistics, existing 200～6,000,000 people of the U.S. are ill.Japanese this disease that claims is overworking death, and there are 150 mayors in Japan because of overworked for a long time in nearly 5 years, suffers from this disease and deadly dying.China does not still have statistics at present, but not rarely seen according to clinical observation, and is many with the brain worker.Along with Chinese economic development, modern fast pace and competition, increasing from the pressure of each side such as life, work, study, the sickness rate of fatigue syndrome is in rising trend.1988 by the Center for Disease Control definite designation.In October, 1999, new edition " practical internal medicine " has been recorded chronic fatigue syndrome.Should disease only be clinical diagnosis at present, its fatigue can not solve by having a rest, and does not find to cause tired internal medicine or psychiatric department disease, so still can not make laboratory diagnosis, does not also propose effective Therapeutic Method.Therefore still there is not this sick Chinese and western drugs of treatment.Because the primary disease course of disease is longer, generally more than half a year, several years very then, have a strong impact on patient's study and work efficiency.Therefore, the active drug of development treatment chronic fatigue syndrome disease is one of research topic of present medical educational circles concern, is significant, and has good prospect again.At present, the medicine of treatment chronic fatigue syndrome still belongs to blank.
The object of the present invention is to provide a kind of medicine that can effectively treat chronic fatigue syndrome.
Technical scheme of the present invention: claim 1.
Beneficial effect of the present invention: medicine of the present invention carries out clinical trial with the attached First Academy of Heilongjiang Province university of TCM, the Heilongjiang Province Fifth Academy of Aerospace Industry, Affiliated Hospital of Heilongjiang Inst. of Integration of Traditional Chinese and Western Medicine (C three tame provincial hospitals.Test objective: investigate leading position and the safety of its curative effect in similar drug, so set up matched group, the contrast medicine is selected eutherapeutic Radix Et Caulis Acanthopanacis Senticosi brain ichor for use, has observed 432 examples altogether, and medicine wherein of the present invention is observed 325 examples, and matched group is observed 107 examples.Result of the test shows: medicine of the present invention is taken safe and reliable, and is without any side effects, and significant treatment, the work and rest irregular chronic fatigue syndrome that cause overworked because of working and learning arranged.Disease is seen fatigue and weakness, dizziness and distending sensation of the head, and thinking is not concentrated, distending pain over the hypochondrium, bitter taste in the mouth and dry throat or pharyngalgia, anorexia, it is uncomfortable to defecate, being irritable and getting angry easily, tension headache, myalgia, insomnia forgetfulness or drowsiness etc.(for details see attached table 1～2) table 1 observe two groups take medicine before and after symptom variation relatively
Main symptom grade main symptom grade symptom U P
++++ +++ ++ + - ++++ +++ ++ + -
Spiritlessness and sparing of words controls preceding 32 160 84 49 0 11 53 26 17 0
4.12 ＜0.05
Fatigue and asthenia is controlled back 7 45 84 87 102 5 32 28 26 18
Control preceding 15 90 136 52 32 5 28 49 17 8
5.75 ＜0.05
The stomach poor appetite is controlled back 3 16 53 104 149 2 15 36 32 22 less
Dull pain in the epigastrium controls preceding 43 103 72 58 49 14 35 24 19 15
1.96 ＜0.05
Abdominal distention after meal is controlled back 14 62 78 79 92 9 21 28 30 19 and is seen big loose stool and control preceding 0 45 86 87 107 pairs 0 14 29 28 36
2.11 ＜0.05
The not well back 0 21 66 108 120 02 18 42 45 of controlling
The breast side of body, few abdomen control preceding 66 68 83 86 12 21 23 27 29 7
2.36 ＜0.05
Distending pain is controlled back 28 36 59 151 51 13 18 31 30 15
Belch controls preceding 0 26 95 87 117 08 31 29 39
1.97 ＜0.05
Acid regurgitation is controlled back 0 17 68 99 141 01 17 29 51
Control preceding 52 113 108 52 0 16 38 36 17 0
Control back 8 49 86 103 79 according to 6 12 48 28 13 2.79＜0.05 examines irritated irritability
Insomnia and dreamful sleep or control preceding 38 92 133 62 0 13 31 44 19 0
2.51 ＜0.05
Hypersomnia is controlled back 8 37 78 90 112 6 20 36 42 8
Bitter taste, dry pharynx control preceding 6 82 107 90 40 2 28 35 29 13
3.37 ＜0.05
Or pharyngalgia is controlled back 1 23 70 117 114 3 20 29 46 9
The dizziness and distending sensation of the head thinking controls preceding 88 93 116 28 0 27 32 38 10 0
3.42 ＜0.05
Concentrated, forgetful back 14 38 66 81 126 17 22 28 33 7 groups of headaches, muscle controlled are controlled preceding 32 73 182 38 0 group 10 18 61 18 0
3.18 ＜0.05
Bitterly, arthralgia is controlled back 2 18 125 76 104 26 54 31 14
Nervous breathing hard controls preceding 0 12 97 173 43 04 32 57 14
1.00 ＞0.05
Or back 07 64 169 75 02 26 58 21 is controlled in sweating
Through carrying out statistical procedures with the Ridit check, the present invention is remarkable to the chronic fatigue syndrome therapeutic effect, and there were significant differences with observation group.
Table 2 is observed two groups of back invalid % of the Comparison of therapeutic table group n recovery from illness % effective % of produce effects % that take medicine and is more shown total effectively % observation group 325 88 (27.1) 115 (35.3) 98 (30.2) 24 (7.4) 62.5 92.6 matched groups 107 28 (24.3) 30 (28.0) 32 (30.0) 17 (5.9) 54.21 81.1 of %
Analyze u=-2.05, P＜0.05 through Ridit.
Toxicity test: through animal acute toxicity test and long term toxicity test, this medicine is without any side effects.(for details see attached table 3～6)
Table 3 the present invention is to rat body weight gain result (g, X ± SD)
Weight increase weight % after the body weight administration before group number of animals (only) administration
Blank 20 94.8 ± 10.1 235.37 ± 8.1 136.7 141.0
Low dose group 20 102.2 ± 9.9 231.7 ± 11.6 120.1 125.6
Middle dosage group 20 97.1 ± 8.2 230.2 ± 10.8 132.6 140.5
High dose group 20 93.8 ± 9.1 238.2 ± 13.1 138.6 143.9
Table 4 the present invention is to rat hematological indices testing result (X ± SD)
Group number of animals RBC Hb WBC WBC classify (%)
(only) (* 10
12/ L) (g/L) (* 10
9/ L) LY GR
Blank 20 4.10 ± 0.32 128 ± 9.2 7.24 ± 1.61 68.7 ± 5.4 25.1 ± 3.4
Low dose group 20 4.86 ± 0.42 130 ± 10.5 8.01 ± 1.85 71.4 ± 4.6 20.6 ± 5.8
Middle dosage group 20 4.71 ± 0.56 127 ± 8.2 7.65 ± 2.13 69.2 ± 3.2 24.1 ± 4.3
High dose group 20 4.80 ± 0.31 131 ± 11.7 7.95 ± 1.74 72.8 ± 5.8 21.7 ± 5.6
Table 5 the present invention learns index testing result (X ± SD) to the rat blood biochemical
Group number of animals BUN Grea SGPT SGOT
(only) be (μ mol/L) (nmol/L) (nmol/L) (mmol/L)
Blank 20 5.7 ± 0.9 80.1 ± 10.5 71.5 ± 11.6 113.8 ± 30.4
Low dose group 20 6.1 ± 1.0 76.8 ± 12.4 64.2 ± 11.4 111.7 ± 17.9
Middle dosage group 20 5.5 ± 1.5 78.2 ± 8.8 69.3 ± 8.9 108.9 ± 25.4
High dose group 20 6.1 ± 1.2 77.9 ± 12.1 70.0 ± 12.4 110.8 ± 19.9
Table 6 the present invention is to big white mouse Main Organ Coefficients result of calculation (dosage group 20 0.49 ± 0.03 3.54 ± 0.25 0.25 ± 0.04 0.86 ± 0.17 0.72 ± 0.15 high dose group 20 0.51 ± 0.03 3.61 ± 0.32 0.27 ± 0.03 0.90 ± 0.15 0.68 ± 0.11 in group number of animals (only) heart liver spleen lungs kidney blank 20 0.50 ± 0.03 3.61 ± 0.32 0.31 ± 0.01 0.90 ± 0.13 0.74 ± 0.13 low dose group 20 0.52 ± 0.04 3.40 ± 0.27 0.28 ± 0.03 0.82 ± 0.14 0.65 ± 0.11 of % X ± SD)
Pharmacodynamics test: the present invention carries out pharmacodynamic experiment with basic, normal, high three dosage groups, and experimental result shows that this medical instrument has analgesia, calmness, improvement study, memory, anti-hypoxia, resisting fatigue, and the effect that improves immune function.(for details see attached table 7～13)
Table 7 the present invention is to the analgesic activity of rat (hot plate method X ± SD)
Different time (branch) 30 threshold of pain differences 60 behind group number of animals (only) dosage g (ml)/kg medicine
Low dosage 20 6.9 2.05 ± 2.35 2.85 ± 3.03
Middle dosage 20 13.8 4.45 ± 5.62 3.85 ± 3.99
High dose 20 27.6 5.35 ± 4.55 3.35 ± 5.09
Sun is to medicine 20 (2.6) 48.5 ± 2.69 48.5 ± 2.69 "
Matched group 20 equivalent 1.15 ± 2.75 1.45 ± 2.95
Compare * P＜0.05 * * P＜0.01 with matched group.
Table 8 the present invention is to the analgesic activity of rat (writhing method X ± SD)
Group number of animals (only) dosage g (ml)/kg turned round the body number of times in 20 minutes
Low dosage 20 6.9 19.7 ± 6.87**
Middle dosage 20 13.8 13.2 ± 11.6**
High dose 20 27.6 12.2 ± 4.62**
Sun is to medicine 20 (2.6) 0.1 ± 0.3***
Contrast medicine 20 equivalent 48.4 ± 17.5
Compare * * P＜0.01, * * * P＜0.001 with the blank group.
Table 9 the present invention is to the sedation of rat (X ± SD)
The movable number of times (inferior) of group number of animals (only) dosage g (ml)/kg
Low dosage 20 6.9 227.5 ± 52.3**
Middle dosage 20 13.8 187.6 ± 49.7**
High dose 20 27.6 160.7 ± 51.7**
Sun is to medicine 20 2.6 199.3 ± 52.1**
Matched group 20 358.2 ± 60.8** and matched group be p＜0.01 relatively.Table 10 the present invention remembers the improvement effect (X ± SD) of obstacle again to rat due to the scopolamine
Dosage number of animals errors number group in incubation period 5
(/kg po) (only) (second) (inferior) contrast (tap water) 20ml 20 1.88 ± 1.36 1.29 ± 4.33
Δ P＜0.05, Δ Δ P＜0.01 are compared with control group in dosage group+moulding 13.8g 20 16.41 ± 15.34 4.76 ± 5.83* low dose group+moulding 6.9g 20 16.82 ± 19.14 5.29 ± 6.423 in moulding hyoscine 2mg 20 22.12 ± 16.68 Δ Δs 9.12 ± 5.19 Δs positive drug+moulding 2.6g 20 17.65 ± 17.94 4.24 ± 4.76* high dose group+moulding 27.6g 20 18.06 ± 16.71 4.82 ± 6.64. (dosage 20 13.8 21.65 ± 1.98** low dosage 20 6.9 23.13 ± 2.78** sun is to the blank group of medicine 20 (2.6) 20.12 ± 3.32* 20 15.77 ± 3.74 each medication group and blank group control group * P＜0.05 relatively, * * P＜0.01 among group number of animals (only) dosage g (ml)/kg swimming time (min) the high dose 20 27.6 28.89 ± 2.17** of X ± SD) to the impact of rats'swimming time in table 11 the present invention. (dosage 20 13.8 22.54 ± 1.99** low dosage 20 6.9 18.55 ± 3.35** sun is to the blank group of medicine 20 (2.6) 24.13 ± 2.78** 20 12.97 ± 1.87 each medication group and blank group * P＜0.05 relatively, * * P＜0.01 among group number of animals (only) dosage g (ml)/kg time-to-live (min) the high dose 20 27.6 29.76 ± 2.90** of X ± SD) to the effect of rat normal pressure resistant anoxia in table 12 the present invention. (the group number of animals dosage serum HD50 refers to serum coagulation spleen coefficient to the Rats with Spleen-deficiency Immune Effects in table 13 the present invention of X ± SD)
(only), (g/kg) number, (HC50) index, (K), (mg/g) dosage 20 13.8 885 ± 234* 176 among high dose 20 2.76 897 ± 290 189 ± 22.3* 4.56 ± 0.89 ± 19.8 4.21 ± 0.73 low dosages 20 6.9 852 ± 215 181 ± 20.0*, 4.77 ± 0.94 sun are to medicine 20, (2.6) 813 ± 228 190 ± 26.6* 4.11 ± 0.67 blank group 20/997 ± 287* 213 ± 28.9** 5.81 ± 1.06** model group 20/685 ± 199 185 ± 25.7 3.87 ± 1.02
Each medication group compares * p＜0.05, * * p＜0.01 with blank group.
A most preferred embodiment of the present invention is described in detail in detail below, get Radix Ginseng Rubra 2.9g, Radix Bupleuri 4.0g, Radix Astragali 5.1g, Radix Curcumae 2.1g, Rhizoma Cyperi 2.1g, Radix Polygalae 2.5g, Rhizoma Chuanxiong 2.1g, Fructus Gardeniae 2.1g, Arisaema Cum Bile 1.5g, Fructus Amomi 0.8g, with Radix Curcumae, Radix Bupleuri, Fructus Amomi, Rhizoma Cyperi, Rhizoma Chuanxiong extracts volatile oil, medicinal liquid behind the extraction volatile oil filters, filtrate and medicinal residues are standby, all the other Radix Ginseng Rubra, the Radix Astragali, Radix Polygalae, Fructus Gardeniae, Arisaema Cum Bile is given as one thinks fit cataclasm, add above-mentioned medicinal residues, decoct with water three times, each 2 hours, collecting decoction, filter, merge with the medicinal liquid of carrying behind the oil, heating is concentrated to the clear paste of relative density 1.10～1.15 (80 ℃ of heat are surveyed), adds ethanol and makes and contain the alcohol amount and reach 70%, left standstill 24 hours, filter, filtrate recycling ethanol is not to there being the alcohol flavor, and residual liquid adds 2 times of water gagings makes dispersion, the centrifugal precipitate that goes, centrifugal liquid adds with the dissolved volatile oil of an amount of Tween 80, and it is an amount of to add water behind the adding simple syrup mix homogeneously, and the packing sterilization forms.Oral each 2-3 props up, every day 3 times, every 10ml.
Second most preferred embodiment of the present invention, get Radix Ginseng Rubra 2.5g, Radix Bupleuri 4.4g, Radix Astragali 5.5g, Radix Curcumae 2.5g, Rhizoma Cyperi 2.5g, Radix Polygalae 2.9g, Rhizoma Chuanxiong 2.5g, Fructus Gardeniae 2.5g, Arisaema Cum Bile 1.9g, Fructus Amomi 1.2g, with Radix Curcumae, Radix Bupleuri, Fructus Amomi, Rhizoma Cyperi, Rhizoma Chuanxiong extracts volatile oil, medicinal liquid behind the extraction volatile oil filters, filtrate and medicinal residues are standby, all the other Radix Ginseng Rubra, the Radix Astragali, Radix Polygalae, Fructus Gardeniae, Arisaema Cum Bile is given as one thinks fit cataclasm, add above-mentioned medicinal residues, decoct with water three times, each 2 hours, collecting decoction, filter, merge with the medicinal liquid of carrying behind the oil, heating is concentrated to the clear paste of relative density 1.10～1.15 (80 ℃ of heat are surveyed), adds ethanol and makes and contain the alcohol amount and reach 70%, left standstill 24 hours, filter, filtrate recycling ethanol is not to there being the alcohol flavor, and residual liquid adds 2 times of water gagings makes dispersion, the centrifugal precipitate that goes, centrifugal liquid adds with the dissolved volatile oil of an amount of Tween 80, and it is an amount of to add water behind the adding simple syrup mix homogeneously, and the packing sterilization forms.Oral each 2-3 props up, every day 3 times, every 10ml.
Claims (1)
1, Lifuji oral liquor, it is a kind of medicine for the treatment of chronic fatigue syndrome, it is characterized in that: composition that drug formulation is contained and shared parts by weight are 2.5～2.9 parts of Radix Ginseng Rubra, 4.0～4.4 parts of Radix Bupleuri, 5.1～5.5 parts of the Radixs Astragali, 2.1～2.5 parts of Radix Curcumaes, 2.1～2.5 parts of Rhizoma Cyperis, 2.5～2.9 parts of Radix Polygalaes, 2.1～2.5 parts of Rhizoma Chuanxiongs, 2.1～2.5 parts of Fructus Gardeniaes, 1.5～1.9 parts of Arisaema Cum Bile, 0.8～1.2 part of Fructus Amomi, with Radix Curcumae, Radix Bupleuri, Fructus Amomi, Rhizoma Cyperi, Rhizoma Chuanxiong extracts volatile oil, medicinal liquid behind the extraction volatile oil filters, filtrate and medicinal residues are standby, all the other Radix Ginseng Rubra, the Radix Astragali, Radix Polygalae, Fructus Gardeniae, Arisaema Cum Bile, give as one thinks fit cataclasm, add above-mentioned medicinal residues, decoct with water three times, each 2 hours, collecting decoction, filter, merge with the medicinal liquid of carrying behind the oil, heating is concentrated to the clear paste of relative density 1.10～1.15 (80 ℃ of heat are surveyed), add ethanol and make and contain alcohol amount and reach 70%, left standstill 24 hours, filter, filtrate recycling ethanol is to there not being the alcohol flavor, residual liquid adds 2 times of water gagings makes dispersion, the centrifugal precipitate that goes, and centrifugal liquid adds with the dissolved volatile oil of an amount of Tween 80, it is an amount of to add water behind the adding simple syrup mix homogeneously, and the packing sterilization forms.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 01114111 CN1238041C (en) | 2001-06-18 | 2001-06-18 | Lifuji oral liquor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 01114111 CN1238041C (en) | 2001-06-18 | 2001-06-18 | Lifuji oral liquor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1391919A true CN1391919A (en) | 2003-01-22 |
| CN1238041C CN1238041C (en) | 2006-01-25 |
Family
ID=4660786
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 01114111 Expired - Lifetime CN1238041C (en) | 2001-06-18 | 2001-06-18 | Lifuji oral liquor |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1238041C (en) |
-
2001
- 2001-06-18 CN CN 01114111 patent/CN1238041C/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CN1238041C (en) | 2006-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1157196C (en) | Galenic preparation for prevention and treatment of hepatocarcinoma | |
| CN100342889C (en) | Chinese medicine for treating gout | |
| CN1742939A (en) | Medicine for treating pulmonary fibrosis and preparing method | |
| CN1824035A (en) | Swim bladder kidney nourishing preparation and its preparation method | |
| CN1840006A (en) | Medicine for treating aplastic anemia | |
| CN1927331A (en) | Chinese medicine preparation for curing chronic heart failure | |
| CN1686377A (en) | Chuankezhi (pant treating) powder injection and its preparation method | |
| CN1478508A (en) | Chinese medicinal composition for treating fatty liver and its preparation method | |
| CN1060657C (en) | Nourishing medicine for preventing and curing toxic and side effect after tumor radiotherapy and chemotherapy and preparation method | |
| CN1748748A (en) | Little leaf deervetch herb preparation for pregnant woman and new preparing method | |
| CN1686467A (en) | Zuanshanfeng wind damp oil and its preparation method | |
| CN1692938A (en) | Compound traditional Chinese medicine for improving eyesight and its prepn. method | |
| CN1391919A (en) | Lifuji oral liquor | |
| CN1276764C (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating iron-deficiency anemia | |
| CN1876112A (en) | A medicine for treating gastric disease and preparation method thereof | |
| CN1541691A (en) | Acute icterohepatitis treating Chinese traditional medicine and its preparation | |
| CN1245199C (en) | Oral medicinal composition for treating diabetes | |
| CN1079396A (en) | Intelligence-enhancing pharmaceutical preparation | |
| CN1475261A (en) | Medicine for treating gastral cavity pain and its preparation method | |
| CN1850185A (en) | Yixinshu Injecta for retaliation of Qi and pulse and promotion of blood circulation and removing of blood stasis, and preparing method therefor | |
| CN1244340C (en) | Chinese medicine for treating coronary heart disease and angina pectoris and its preparing process | |
| CN1446554A (en) | Medicine for treating acute cholecystitis and chronic cholecystitis and its preparing method | |
| CN1258365C (en) | Pharmacetutical composition for treating cardiovascular and cerebrovascular disease and its preparing process | |
| CN1081926C (en) | Chinese medicine for preventing tumour and use in making drug | |
| CN1686337A (en) | Traditional Chinese medicine for anti depression |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Liu Yuhui Document name: Notification to Pay the Fees |
|
| DD01 | Delivery of document by public notice |
Addressee: Liu Yuhui Document name: Notification to Pay the Fees |
|
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20030122 Assignee: Heilongjiang days Ge Pharmaceutical Co., Ltd. Assignor: Liu Yuhui Contract record no.: 2014230000138 Denomination of invention: Lifuji oral liquor Granted publication date: 20060125 License type: Exclusive License Record date: 20140421 |
|
| LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
| EM01 | Change of recordation of patent licensing contract |
Change date: 20141203 Contract record no.: 2014230000138 Assignee after: Harbin traditional Chinese medicine four factory Co., Ltd. Assignee before: Heilongjiang days Ge Pharmaceutical Co., Ltd. |
|
| LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
| DD01 | Delivery of document by public notice |
Addressee: Liu Yuhui Document name: Notification that Application Deemed not to be Proposed |
|
| DD01 | Delivery of document by public notice | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| CB03 | Change of inventor or designer information |
Inventor after: Zhang Xiuling Inventor before: Liu Yuhui |
|
| COR | Change of bibliographic data | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20170223 Address after: Nanjing Road East three street in Heilongjiang city of Harbin Province Traditional Chinese medicine 150025 Limin development zone four factory Patentee after: Zhang Xiuling Address before: 150001 Wenchang street, Nangang District, Heilongjiang, China, No. 1, No. Patentee before: Liu Yuhui |
|
| DD01 | Delivery of document by public notice |
Addressee: Liu Yuhui Document name: Notification of Passing Examination on Formalities |
|
| DD01 | Delivery of document by public notice | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20180808 Address after: 150025 the four Chinese herbal medicine factory of Nanjing Road East three street, liming Development Zone, Harbin, Heilongjiang Patentee after: Harbin traditional Chinese medicine four factory Co., Ltd. Address before: 150025 the four Chinese herbal medicine factory of Nanjing Road East three street, liming Development Zone, Harbin, Heilongjiang Patentee before: Zhang Xiuling |
|
| TR01 | Transfer of patent right | ||
| CX01 | Expiry of patent term |
Granted publication date: 20060125 |
|
| CX01 | Expiry of patent term |